Our Signaturetereo-logo-whiteProcess

What is Tereo®?

Tereo (Greek) means ‘to protect, to keep guard over, and preserve’. The patented and proprietary Tereo process delicately preserves the tissue such that it uniquely enhances the retention of the native and regenerative qualities of fresh amniotic membrane. Tereo allows storage of tissue in a dry state, at room temperature (25°C), and is ready to use at the instance it is needed, straight from the pack.

We’re fully licensed by the Human Tissue Authority

How does Tereo work?

Tereo processing has been developed over 13 years of academic research at the University of Nottingham, Ophthalmology Department. NuVision have adopted Tereo with the objective of providing surgeons with a high quality and reliable allograft-product compositionally comparable to fresh amnion. NuVision™ is regulated and licensed (licence number 22656) in the UK by the Human Tissue Authority (HTA) and all amnion donors are screened in accordance with current practices.

We call Tereo™ processed amnion, Omnigen™. Omnigen™ can be distributed and stored at room temperature on the shelf of any medical facility, allowing surgeons to access amnion whenever and wherever they need it, with the reassurance of stability and consistency. Omnigen™ can be directly applied to the ocular surface with ease, allowing rapid in vivo rehydration from eye moisture that initiates the prolonged release of natural repair inducing constituents.

How effective is Tereo?

When applying the Tereo process to amnion, the amnion is carefully isolated from the placental mass with gentle ‘hands free’ cleaning of the tissue to effectively remove any blood contamination. The process then implements proprietary steps to completely remove the irregular and inhibitory jelly-like substance on the stromal aspect of the amnion, the ‘spongy layer’. Researchers at Nottingham was the first to fully recognise the importance of removing the spongy layer, and therefore patented this process.

The fresh tissue is then delicately stabilised, within 6 hours of birth, using a patenting Low Temperature Vacuum Dehydration to produce a sterile, standardised and minimally manipulated highly malleable biological matrix. This retains the inherent trophic regenerative factors, the profile being equivalent to fresh amniotic membrane, which is only released once placed and rehydrated at the site of the wound.

Why is Tereo a game changer?

Human amniotic membrane (amnion) has been successfully utilised for decades as an effective surgical adjunct for a wide variety of indications. However, its full potential has been limited due to its perishability, logistic challenges, and variability in the quality from piece to piece. NuVision has overcome these limitations by introducing the Tereo manufacturing process.

Our Research from Nottingham

  1. Paris Fdos, S., E.D. Goncalves, M.S. Campos, E.H. Sato, H.S. Dua, and J.A. Gomes, Amniotic membrane transplantation versus anterior stromal puncture in bullous keratopathy: a comparative study. Br J Ophthalmol, 2013. 97(8): p. 980-4.Aug
  2. Allen, C.L., G. Clare, E.A. Stewart, M.J. Branch, O.D. McIntosh, M. Dadhwal, H.S. Dua, and A. Hopkinson, Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing. PLoS One, 2013. 8(10): p. e78441
  3. Chau, D.Y., S.V. Brown, M.L. Mather, V. Hutter, N.L. Tint, H.S. Dua, F.R. Rose, and A.M. Ghaemmaghami, Tissue transglutaminase (TG-2) modified amniotic membrane: a novel scaffold for biomedical applications. Biomed Mater, 2012. 7(4): p. 045011.Aug
  4. Nubile, M., H.S. Dua, M. Lanzini, M. Ciancaglini, R. Calienno, D.G. Said, A. Pocobelli, R. Mastropasqua, and P. Carpineto, In vivo analysis of stromal integration of multilayer amniotic membrane transplantation in corneal ulcers. Am J Ophthalmol, 2011. 151(5): p. 809-822 e1.May
  5. Zakaria, N., C. Koppen, V. Van Tendeloo, Z. Berneman, A. Hopkinson, and M.J. Tassignon, Standardized limbal epithelial stem cell graft generation and transplantation. Tissue Eng Part C Methods, 2010. 16(5): p. 921-7.Oct
  6. Miri, A., B. Al-Deiri, and H.S. Dua, Long-term outcomes of autolimbal and allolimbal transplants. Ophthalmology, 2010. 117(6): p. 1207-13.Jun
  7. Dua, H.S., I. Rahman, A. Miri, and D.G. Said, Variations in amniotic membrane: relevance for clinical applications. Br J Ophthalmol, 2010. 94(8): p. 963-4.Aug
  8. Said, D.G., M. Nubile, T. Alomar, A. Hopkinson, T. Gray, J. Lowe, and H.S. Dua, Histologic features of transplanted amniotic membrane: implications for corneal wound healing. Ophthalmology, 2009. 116(7): p. 1287-95.Jul
  9. Rahman, I., D.G. Said, V.S. Maharajan, and H.S. Dua, Amniotic membrane in ophthalmology: indications and limitations. Eye (Lond), 2009. 23(10): p. 1954-61.Oct
  10. Gicquel, J.J., H.S. Dua, A. Brodie, I. Mohammed, H. Suleman, E. Lazutina, D.K. James, and A. Hopkinson, Epidermal growth factor variations in amniotic membrane used for ex vivo tissue constructs. Tissue Eng Part A, 2009. 15(8): p. 1919-1927.Aug
  11. Nubile, M., H.S. Dua, T.E. Lanzini, P. Carpineto, M. Ciancaglini, L. Toto, and L. Mastropasqua, Amniotic membrane transplantation for the management of corneal epithelial defects: an in vivo confocal microscopic study. Br J Ophthalmol, 2008. 92(1): p. 54-60.Jan
  12. Hopkinson, A., V.A. Shanmuganathan, T. Gray, A.M. Yeung, J. Lowe, D.K. James, and H.S. Dua, Optimization of amniotic membrane (AM) denuding for tissue engineering. Tissue Eng Part C Methods, 2008. 14(4): p. 371-81.Dec
  13. Maharajan, V.S., V. Shanmuganathan, A. Currie, A. Hopkinson, A. Powell-Richards, and H.S. Dua, Amniotic membrane transplantation for ocular surface reconstruction: indications and outcomes. Clin Experiment Ophthalmol, 2007. 35(2): p. 140-7.Mar
  14. Hopkinson, A., R.S. McIntosh, P.J. Tighe, D.K. James, and H.S. Dua, Amniotic membrane for ocular surface reconstruction: donor variations and the effect of handling on TGF-beta content. Invest Ophthalmol Vis Sci, 2006. 47(10): p. 4316-22.Oct
  15. Hopkinson, A., R.S. McIntosh, V. Shanmuganathan, P.J. Tighe, and H.S. Dua, Proteomic analysis of amniotic membrane prepared for human transplantation: characterization of proteins and clinical implications. J Proteome Res, 2006. 5(9): p. 2226-35.Sep
  16. Ainsworth, G., A. Rotchford, H.S. Dua, and A.J. King, A novel use of amniotic membrane in the management of tube exposure following glaucoma tube shunt surgery. Br J Ophthalmol, 2006. 90(4): p. 417-9.Apr
  17. Hopkinson, A., R.S. McIntosh, R. Layfield, J. Keyte, H.S. Dua, and P.J. Tighe, Optimised two-dimensional electrophoresis procedures for the protein characterisation of structural tissues. Proteomics, 2005. 5(7): p. 1967-79.May
  18. Gomes, J.A., A. Romano, M.S. Santos, and H.S. Dua, Amniotic membrane use in ophthalmology. Curr Opin Ophthalmol, 2005. 16(4): p. 233-40.Aug
  19. Dua, H.S., J.A. Gomes, A.J. King, and V.S. Maharajan, The amniotic membrane in ophthalmology. Surv Ophthalmol, 2004. 49(1): p. 51-77.Jan-Feb
  20. Moore, J.E., H.S. Dua, A.B. Page, A.D. Irvine, and D.B. Archer, Ocular surface reconstruction in LOGIC syndrome by amniotic membrane transplantation. Cornea, 2001. 20(7): p. 753-6.Oct
  21. Joseph, A., H.S. Dua, and A.J. King, Failure of amniotic membrane transplantation in the treatment of acute ocular burns. Br J Ophthalmol, 2001. 85(9): p. 1065-9.Sep
  22. Dua, H.S. and A. Azuara-Blanco, Limbal stem cells of the corneal epithelium. Surv Ophthalmol, 2000. 44(5): p. 415-25.Mar-Apr
  23. Dua, H.S. and A. Azuara-Blanco, Amniotic membrane transplantation. Br J Ophthalmol, 1999. 83(6): p. 748-52.Jun

Interested in purchasing Omnigen?

Register your interest

Have a question about our products or pipelines?

Speak to our team of experts